9:04 AM
 | 
Jul 11, 2018
 |  BC Innovations  |  Translation in Brief

Poisoning the stromal chalice

Why an ADC could be the right modality to kill tumors by targeting their stroma

A study published in the Journal of Clinical Investigation suggests antibody-drug conjugates targeting the tumor stroma could treat cancers by co-opting a stromal mechanism to feed cytotoxic drugs to the surrounding tumor cells.

Tumor-associated stroma, which comprises fibroblasts and connective tissue components, is a non-malignant feature of all solid tumors that supports tumor growth and can physically protect tumor cells from exposure to therapies.

The JCI study, led by Brad St. Croix at the National Cancer Institute (NCI), built on St. Croix’s 2012 Cancer Cell paper that used a mAb against a stroma-enriched antigen, anthrax toxin receptor 1 (ANTXR1; TEM8), to deplete tumor stroma and starve tumor cells (see “A TEM To Kill”).

While the ANTXR1-targeted mAb slowed the growth of solid tumors in multiple mouse models, it did not eradicate them, said St. Croix, a senior...

Read the full 671 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$85 USD
More Info >